Navigation Links
ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Date:7/29/2008

LEUVEN, Belgium, July 30 /PRNewswire-FirstCall/ --

- Shares Acquired From Biggar Limited

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, today announces that a group of private investors based in Belgium have together acquired an 8% stake in the Company. Their stake was purchased from Biggar Limited, a charitable foundation that is ThromboGenics largest shareholder. Biggar now holds a 9.8% stake in ThromboGenics following this transaction, and has informed the company that it intends to remain an important shareholder in ThromboGenics for the long term.

This transaction was managed by Petercam.

Prof. Desire Collen, Chairman and CEO of ThromboGenics, commenting on today's announcement, said: "We are very pleased that we have been able to attract such a group of high net worth individuals to become shareholders in ThromboGenics, particularly given their long term commitment to the Company. We are confident that we will be able to generate significant value for all our shareholders over the next several years based on the exciting prospects for microplasmin in the treatment of back of the eye disease, our other pipeline products, including TB-402 for deep vein thrombosis, as well as the significant potential that we see for TB-403 in the treatment of cancer, which was recently licensed to Roche."

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. ThromboGenics N.V. - Business Update
3. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
4. ThromboGenics Announces 2007 Full Year Results
5. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
8. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
9. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
10. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 25, 2015 Having added two International ... part of 2014, ITRA Global proudly announced recently the ... Tenant Representative Alliance, based in the United States, is ... and occupiers of commercial real estate. , Saltwood ... in Poland that exclusively advises occupiers of office space, ...
(Date:3/25/2015)... the HAGUE, Netherlands , March 25, ... LES Stimulation therapy for chronic gastro-esophageal reflux disease (GERD) ... [ Surgery . 2015; 157(3):556-567 ], establishing ... therapy. The study included 25 patients ... years and taking prescribed daily proton pump inhibitor (PPI) ...
(Date:3/25/2015)... 2015 /CNW/ - The Gairdner Foundation is pleased ... Awards, recognizing some of the most significant medical ... Among the world,s most esteemed medical research prizes, ... provide a $100,000 (CDN) prize to each scientist for their ... research and innovation across the country, inspiring the ...
(Date:3/25/2015)... 2015 FDNA®, the pioneer in ... Face2Gene, allowing geneticists around the globe to ... as mobile devices. Face2Gene® facilitates detection of facial dysmorphic ... comprehensive and up-to-date genetic references. The date of the ... 2015, in Salt Lake City, UT ...
Breaking Biology Technology:International Organization Expands its Global Reach to Warsaw, Poland 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015 2
... EST, HOPKINTON, Mass., Oct. 23 Caliper ... a conference call discussing the,company,s third quarter 2008 ... 10. Kevin Hrusovsky, President and Chief Executive Officer ... call. Management will,discuss operational and financial results and ...
... Oct. 23 Techne Corporation,(Nasdaq: TECH ) announced ... a dividend of $0.25 per share for the quarter ... November 17, 2008 to all common,shareholders of record on ... Chairman and Chief Executive,Officer, said, "I am very pleased ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, ... entitled "A Phase I,Study to Evaluate Systemic ... Patients with Advanced Malignancies" will be available ... Immunotherapy, the official,journal of the International Society ...
Cached Biology Technology:Caliper Life Sciences' Third Quarter 2008 Financial Results Conference Call Notice 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 3
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... for Integrative Legume Research (CILR) has lodged a complete ... CILR researchers screened legumes (plants which obtain useable nitrogen ... and they identified a number of compounds which could ... tumours. Without an adequate blood supply tumours stop growing ...
... can retain a good memory even in your twilight years ... believe they can control their memory are more likely to ... march of time. These are the conclusions of a new ... , The study demonstrates a link between actual cognitive functioning ...
... differences between humans and chimpanzees are due more to ... themselves, researchers from Yale, the University of Chicago, and ... the 9 March 2006 issue of the journal ... for a 30-year-old theory, proposed in a classic paper ...
Cached Biology News:Legume compounds may help cancer treatment 2Confidence in memory performance helps older adults remember 2Most human-chimp differences due to gene regulation ?not genes 2Most human-chimp differences due to gene regulation ?not genes 3